The delivery of peptides or protein drugs via the oral route has always presented a significant challenge. Here, nanoparticles for the oral delivery of liraglutide are prepared. The nanoparticles are composed of the biodegradable carrier materials chitosan and poly-N-(2-hydroxypropyl) methacrylamide (pHPMA). In addition, CSKSSDYQC (CSK) and hemagglutinin-2 (HA2) are introduced into the particles to improve the in vivo bioavailability of liraglutide. The size of the nanoparticles is less than 200 nm, and the encapsulation efficiency is approximately 80%. Compared with the subcutaneously injected liraglutide solution group (100%), the relative bioavailability of the nanoparticle group modified with CSK and HA2 reached 10.12%, which is 2.53 times that of the oral liraglutide solution group. In vivo imaging results showed that pHPMA/HA2-CSK chitosan nanoparticles (pHPMA/HA-CCNPs) are retained in the gastrointestinal tract for up to 12 h, which is beneficial for oral absorption. CSK and HA2 modified pHPMA/chitosan nanoparticles significantly improved liraglutide oral bioavailability and therefore have the potential to be applied for oral administration of peptides and proteins.
UppalSItaliyaKSChitkaraD, et al.
Nanoparticulate-based drug delivery systems for small molecule anti-diabetic drugs: an emerging paradigm for effective therapy. Acta Biomater2018;
81: 20–42.
2.
ScottESMcgrathRTJanuszewskiAS, et al.
HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment. BMJ Open2019;
9: e033059.
3.
NuhohoSGuptaJHansenBB, et al.
Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1-2 oral antidiabetics: systematic review and network meta-analysis.Diabetes Ther2019;
10: 2183–2199.
4.
DE RitterRDE JongMVosRC, et al.
Sex differences in the risk of vascular disease associated with diabetes. Biol Sex Differ2020;
11: 1.
5.
BavumaCSahabanduDMusafiriS, et al.
Atypical forms of diabetes mellitus in Africans and other non-European ethnic populations in low- and Middle-income countries: a systematic literature review. J Glob Health2019;
9: 020401.
6.
Mata-CasesMFranch-NadalJRealJ, et al.
Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: a population-based cross-sectional study. BMJ Open2019;
9: e031281.
7.
AdamsJMPeiHSandovalDA, et al.
Liraglutide modulates appetite and body weight through Glucagon-Like peptide 1 Receptor-Expressing glutamatergic neurons. Diabetes2018;
67: 1538–1548.
8.
RodbardHWBodeBWHarrisSB, the Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigatorset al.
Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with type 2 diabetes: the DUAL IV trial. Diabet Med2017;
34: 189–196.
9.
WuLGaoLCaoY, et al.
Analysis of the protective mechanism of liraglutide on retinopathy based on diabetic mouse model. Saudi J Biol Sci2019;
26: 2096–2101.
10.
WangJKongMZhouZ, et al.
Mechanism of surface charge triggered intestinal epithelial tight junction opening upon chitosan nanoparticles for insulin oral delivery. Carbohydr Polym2017;
157: 596–602.
11.
DruckerDJ.Advances in oral peptide therapeutics. Nat Rev Drug Discov2020;
19: 277–289.
12.
BuckleySTBækdalTAVeggeA, et al.
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med2018;
10: eaar7047.
13.
BanerjeeAIbsenKBrownT, et al.
Ionic liquids for oral insulin delivery. Proc Natl Acad Sci USA2018;
115: 7296–7301.
14.
SgorlaDLechanteurAAlmeidaA, et al.
Development and characterization of lipid-polymeric nanoparticles for oral insulin delivery. Expert Opin Drug Deliv2018;
15: 213–222.
15.
TsaiL-CChenC-HLinC-W, et al.
Development of mutlifunctional nanoparticles self-assembled from trimethyl chitosan and fucoidan for enhanced oral delivery of insulin. Int J Biol Macromol2019;
126: 141–150.
16.
KangSKWooJHKimMK, et al.
Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells. J Biotechnol2008;
135: 210–216.
17.
ZhangPXuYZhuX, et al.
Goblet cell targeting nanoparticle containing drug-loaded micelle cores for oral delivery of insulin. Int J Pharm2015;
496: 993–1005.
18.
AlibolandiMAlabdollahFSadeghiF, et al.
Dextran-b-poly(lactide-co-glycolide) polymersome for oral delivery of insulin: in vitro and in vivo evaluation. J Controll Release2016;
227: 58–70.
19.
LiXWangCLiangR, et al.
The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles. Pharm Res2015;
32: 1017–1027.
20.
ZhuYCAnTLiuY, et al.
Immunoprotective effects of a hemin-binding peptide derived from hemagglutinin-2 against infection with Porphyromonas gingivalis. Mol Oral Microbiol2018;
33: 81–88.
21.
XuYZhengYWuL, et al.
Novel solid lipid nanoparticle with endosomal escape function for oral delivery of insulin. ACS Appl Mater Interfaces2018;
10: 9315–9324.
22.
WangXGuoYQiuL, et al.
Preparation and evaluation of carboxymethyl chitosan-rhein polymeric micelles with synergistic antitumor effect for oral delivery of paclitaxel. Carbohydr Polym2019;
206: 121–131.
23.
ZhangXChytilPEtrychT, et al.
Binding of HSA to macromolecular pHPMA based nanoparticles for drug delivery: an investigation using fluorescence methods. Langmuir2018;
34: 7998–8006.
24.
ScalesCWVasilievaYAConvertineAJ, et al.
Direct, controlled synthesis of the nonimmunogenic, hydrophilic polymer, poly(N-(2-hydroxypropyl)methacrylamide) via RAFT in aqueous media. Biomacromolecules2005;
6: 1846–1850.
25.
YinMShiYSongY, et al.
An intelligent escape system for oral delivery of liraglutide: the perfect match for the gastrointestinal barriers. Mol Pharmaceutics2020;
17: 1899–1909.
26.
MazzottaEDE BenedittisSQualtieriA, et al.
Actively targeted and redox responsive delivery of anticancer drug by chitosan nanoparticles. Pharmaceutics2019;
12: 26.
27.
ParasharPMazharIKanoujiaJ, et al.
Appraisal of anti-gout potential of colchicine-loaded chitosan nanoparticle gel in uric acid-induced gout animal model. Arch Physiol Biochem. Epub ahead of print 18 December 2019. DOI: 10.1080/13813455.2019.1702702.
28.
LiXGuoSZhuC, et al.
Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials2013;
34: 9678–9687.
29.
Attili-QadriSKarraNNemirovskiA, et al.
Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci Usa2013;
110: 17498–17503.
30.
SinghGPaiRS.Optimized self-nanoemulsifying drug delivery system of atazanavir with enhanced oral bioavailability: in vitro/in vivo characterization. Expert Opin Drug Deliv2014;
11: 1023–1032.
31.
SongYShiYZhangL, et al.
Synthesis of CSK-DEX-PLGA nanoparticles for the oral delivery of exenatide to improve its mucus penetration and intestinal absorption. Mol Pharm2019;
16: 518–532.
